SVRA

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Savara Inc

NASDAQ | SVRA

3.60

USD

$0.00

(

0.00%

)

At Close (As of Sep 17, 2025)

$627.40M

Market Cap

-

P/E Ratio

-0.51

EPS

$4.70

52 Week High

$1.89

52 Week Low

HEALTHCARE

Sector

SVRA Chart

Recent Chart
Price Action

SVRA Technicals

Tags:

SVRA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$275K
Total Revenue $0
Cost Of Revenue $275K
Costof Goods And Services Sold $275K
Operating Income -$103M
Selling General And Administrative $25M
Research And Development $78M
Operating Expenses $103M
Investment Income Net -
Net Interest Income $6.5M
Interest Income $6.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $130K
Income Before Tax -$96M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$96M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$102M
Net Income -$96M

Revenue & Profitability

Earnings Performance

SVRA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $202M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $11M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $10M
Intangible Assets Excluding Goodwill $10M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $181M
Other Current Assets $4.8M
Other Non Current Assets -
Total Liabilities $41M
Total Current Liabilities $15M
Current Accounts Payable $4.5M
Deferred Revenue -
Current Debt -
Short Term Debt $116K
Total Non Current Liabilities $27M
Capital Lease Obligations $116K
Long Term Debt $27M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $27M
Other Current Liabilities $10M
Other Non Current Liabilities $87K
Total Shareholder Equity $171M
Treasury Stock -
Retained Earnings -$489M
Common Stock $173K
Common Stock Shares Outstanding $198M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$89M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $130K
Capital Expenditures $25K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$40M
Cashflow From Financing $118M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$995K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$96M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$275K
Total Revenue $0
Cost Of Revenue $275K
Costof Goods And Services Sold $275K
Operating Income -$103M
Selling General And Administrative $25M
Research And Development $78M
Operating Expenses $103M
Investment Income Net -
Net Interest Income $6.5M
Interest Income $6.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $130K
Income Before Tax -$96M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$96M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$102M
Net Income -$96M

SVRA News

SVRA Profile

Savara Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Savara Inc. is a biopharmaceutical company headquartered in Austin, Texas, focused on developing innovative therapies for patients with rare lung diseases. With a commitment to addressing unmet medical needs in the field of respiratory health, Savara's pipeline includes promising candidates targeting various orphan indications. The company's strategic approach combines cutting-edge science with a patient-centric vision, positioning it as a key player in the lung disease therapeutic landscape.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.95%
$92.98
AMZN
-1.03%
$231.62
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ETWO
0.00%
$3.30
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.95%
$92.98
AMZN
-1.03%
$231.62
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ETWO
0.00%
$3.30
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.